Worth reading
32Immaterial
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
86
Millions of yen (amount of improvement in operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending June 20273 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥253 million+31.6%
Operating profit¥-4 million
Ordinary income¥0 million
Net income¥-3 million net income attributable to owners of the parent
Selling, general and administrative expensesRemained flat. Amount and SG&A-to-sales ratio: Not disclosed
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Large projects from domestic pharmaceutical companies, strong performance from domestic academia, lower purchases, an increase in work in progress accompanying higher orders, and flat SG&A expenses. Breakdown of factors by amount: Not disclosed
Segment results
- ServicesLife Science research support services (LSS)Net Sales¥194 millionYear on year against the same period last yearUp 58.1%
- ServicesFunctional materials development support services (FDS)Net Sales¥28 millionYear on year against the same period last yearDown 22.5%
- ServicesBio-manufacturing support services (BMS)Net Sales¥30 millionYear on year against the same period last yearDown 7.6%
Number of employees
65 people consolidated, as of June 2026
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending June 2027 |
| Net Sales | ¥253 million (YoY +31.6%) |
| Operating profit | ¥-4 million |
| Ordinary income | ¥0 million |
| Net income | ¥-3 million (net income attributable to owners of the parent) |
| Selling, general and administrative expenses | Remained flat. Amount and SG&A-to-sales ratio: Not disclosed |
| Segment results | Services Life Science research support services (LSS) / Net Sales ¥194 million / Year on year against the same period last year Up 58.1%, Services Functional materials development support services (FDS) / Net Sales ¥28 million / Year on year against the same period last year Down 22.5%, Services Bio-manufacturing support services (BMS) / Net Sales ¥30 million / Year on year against the same period last year Down 7.6% |
| Breakdown of Factors Affecting the Change | Large projects from domestic pharmaceutical companies, strong performance from domestic academia, lower purchases, an increase in work in progress accompanying higher orders, and flat SG&A expenses. Breakdown of factors by amount: Not disclosed |
| Number of employees | 65 people (consolidated, as of June 2026) |
Items this document does not state (21)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Increased revenue from life sciences research support services for domestic pharmaceutical companies and academia; lower cost of sales due to a decrease in purchases and an increase in work in progress accompanying higher orders; and SG&A expenses remaining flat.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.